← Back to Screener
Passage Bio, Inc. Common Stock (PASG)
Price$11.68
Favorite Metrics
Price vs S&P 500 (26W)39.61%
Price vs S&P 500 (4W)63.31%
Market Capitalization$38.14M
All Metrics
Book Value / Share (Quarterly)$5.89
P/TBV (Annual)0.17x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-9.90
Price vs S&P 500 (YTD)-1.88%
EPS (TTM)$-14.44
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-14.44
EPS (Annual)$-14.35
ROI (Annual)-242.72%
Cash / Share (Quarterly)$14.55
ROA (Last FY)-73.09%
EBITD / Share (TTM)$-14.91
ROE (5Y Avg)-113.18%
Cash Flow / Share (Annual)$-9.90
P/B Ratio2.03x
P/B Ratio (Quarterly)1.96x
Net Income / Employee (Annual)$-2
ROA (TTM)-60.36%
EPS Incl Extra (Annual)$-14.35
Current Ratio (Annual)2.07x
Quick Ratio (Quarterly)2.01x
3-Month Avg Trading Volume0.06M
52-Week Price Return55.22%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.30
52-Week High$20.00
EPS Excl Extra (Annual)$-14.35
CapEx CAGR (5Y)-54.22%
26-Week Price Return43.60%
Quick Ratio (Annual)2.01x
13-Week Price Return-33.61%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.07x
Enterprise Value$-8.162
Book Value / Share Growth (5Y)-2.48%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$14.55
3-Month Return Std Dev120.49%
Net Income / Employee (TTM)$-2
ROE (Last FY)-242.72%
EPS Basic Excl Extra (Annual)$-14.35
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-14.44
ROI (TTM)-135.04%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.69
Price vs S&P 500 (52W)25.39%
Year-to-Date Return0.76%
5-Day Price Return6.26%
EPS Normalized (Annual)$-14.35
ROA (5Y Avg)-62.45%
Month-to-Date Return51.47%
Cash Flow / Share (TTM)$-1.98
EBITD / Share (Annual)$-14.84
ROI (5Y Avg)-113.18%
EPS Basic Excl Extra (TTM)$-14.44
P/TBV (Quarterly)0.27x
P/B Ratio (Annual)1.96x
Book Value / Share (Annual)$5.89
Price vs S&P 500 (13W)-34.30%
Beta2.00x
Revenue / Share (TTM)$0.00
ROE (TTM)-135.04%
52-Week Low$5.12
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.31
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PASGPassage Bio, Inc. Common Stock | — | — | — | — | $11.68 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Passage Bio develops genetic medicines for rare monogenic CNS disorders, including GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The company targets the underlying causes of these neurodegenerative conditions to address significant unmet medical needs.